colitis/edema

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated

FIELD OF THE INVENTION The invention relates to the use of biologically active glutarimide derivatives or pharmaceutically acceptable salts thereof as agents for the treatment of eosinophilic diseases. BACKGROUND Eosinophils are cells of the innate immunity. They are produced in the bone marrow and

FIELD OF THE INVENTION The present invention relates to antibodies to Shiga-like toxins. More particularly, it relates to high titer, monospecific, purified polyclonal antibodies to Shiga-like toxins and methods of preparing and using the antibodies. The invention also relates to the pharmaceutical

BACKGROUND Inflammation often is a bodily response to infection or injury in which cells involved in detoxification and repair are mobilized to the compromised site by inflammatory mediators. The infection or injury can result from any of a variety of causes including acute or chronic disease,

CROSS REFERENCE TO RELATED APPLICATION The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995. BACKGROUND OF THE INVENTION This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives. Nitric Oxide in

BACKGROUND OF THE INVENTION This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines. Nitric Oxide in Biology. The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. National Stage application under 35 U.S.C. .sctn. 371 of International Application PCT/RU2014/000855 (published as WO 2015/072893 A1), filed Nov. 12, 2014, which claims priority to Application RU 2013150861, filed Nov. 14, 2013.